Impact of Neuropathic Post-Zosterian Pain on the Cognition

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier:
NCT00989040
First received: March 13, 2009
Last updated: January 26, 2012
Last verified: January 2012
  Purpose

Pain is defined as a sensorial and emotional phenomenon and lead consequences on the cognition. These consequences could be increased with usual treatment. So the aim of this study is to explore these cognitive consequences.


Condition Intervention Phase
Neuropathic Post-zosterian Pain
Cognition
Drug: usual treatment: Versatis
Phase 1

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Impact of Neuropathic Post-zosterian Pain on the Cognition (NPZ and Cognition)

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • The principal outcome is to explore if the cognition is failed in treated patients suffering of neuropathic post-zosteria pain. [ Time Frame: at day 1 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Study if treated patients with patch (Versatis®) have better cognition than treated patients without patch. [ Time Frame: at day 1 ] [ Designated as safety issue: Yes ]

Enrollment: 100
Study Start Date: March 2009
Study Completion Date: September 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: usual treatment: Versatis
    • To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.
    • To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch.
Detailed Description:

Pilot prospective study with parallel groups

  Eligibility

Ages Eligible for Study:   55 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients who suffer of neuropathic post-zosteria pain

Criteria

Inclusion Criteria:

  • Patient suffering of NPZ pain
  • Over 55 years old
  • Healthy volunteers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00989040

Locations
France
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Investigators
Principal Investigator: Claude Dubray, PUPH CIC-CPC Clermont-Ferrand
  More Information

No publications provided by University Hospital, Clermont-Ferrand

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Clermont-Ferrand
ClinicalTrials.gov Identifier: NCT00989040     History of Changes
Other Study ID Numbers: CHU-0049
Study First Received: March 13, 2009
Last Updated: January 26, 2012
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Clermont-Ferrand:
NPZ
Pain

ClinicalTrials.gov processed this record on July 24, 2014